{"id":"https://openalex.org/W2951695178","doi":"https://doi.org/10.1080/14737167.2019.1629291","title":"Cost-effectiveness of pan-genotypic direct-acting antiviral regimens for treatment of chronic Hepatitis C in the United States","display_name":"Cost-effectiveness of pan-genotypic direct-acting antiviral regimens for treatment of chronic Hepatitis C in the United States","publication_year":2019,"publication_date":"2019-06-17","ids":{"openalex":"https://openalex.org/W2951695178","doi":"https://doi.org/10.1080/14737167.2019.1629291","mag":"2951695178","pmid":"https://pubmed.ncbi.nlm.nih.gov/31204882"},"language":"en","primary_location":{"id":"doi:10.1080/14737167.2019.1629291","doi":"https://doi.org/10.1080/14737167.2019.1629291","is_oa":false,"landing_page_url":"https://doi.org/10.1080/14737167.2019.1629291","pdf_url":null,"source":{"id":"https://openalex.org/S98544388","display_name":"Expert Review of Pharmacoeconomics & Outcomes Research","issn_l":"1473-7167","issn":["1473-7167","1744-8379"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["abdc-c","anvur-scientific","cwts-core","dongbi-d","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320547","host_organization_name":"Taylor & Francis","host_organization_lineage":["https://openalex.org/P4310320547","https://openalex.org/P4310320449"],"host_organization_lineage_names":["Taylor & Francis","Informa"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Expert Review of Pharmacoeconomics & Outcomes Research","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5046835105","display_name":"Stuart C. Gordon","orcid":"https://orcid.org/0000-0001-8666-3849","observed_orcids":["https://orcid.org/0000-0001-8666-3849"]},"institutions":[{"id":"https://openalex.org/I2803043754","display_name":"Henry Ford Hospital","ror":"https://ror.org/0193sb042","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I154057602","https://openalex.org/I2803043754"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Stuart Gordon","raw_affiliation_strings":["Division of Gastroenterology, Henry Ford Hospital, Detroit, MI, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Gastroenterology, Henry Ford Hospital, Detroit, MI, USA","institution_ids":["https://openalex.org/I2803043754"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5100761859","display_name":"Janet S. Lee","orcid":"https://orcid.org/0000-0002-6812-6043","observed_orcids":["https://orcid.org/0000-0002-6812-6043","https://orcid.org/0000-0003-4570-2033"]},"institutions":[{"id":"https://openalex.org/I4210140816","display_name":"Gilead Sciences (United States)","ror":"https://ror.org/056546b03","country_code":"US","type":"company","lineage":["https://openalex.org/I4210140816"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Janet Lee","raw_affiliation_strings":["Gilead Sciences, Inc., Foster City, CA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Gilead Sciences, Inc., Foster City, CA, USA","institution_ids":["https://openalex.org/I4210140816"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5101772448","display_name":"Nathaniel Smith","orcid":"https://orcid.org/0000-0002-9215-8109","observed_orcids":["https://orcid.org/0000-0002-9215-8109"]},"institutions":[],"countries":[],"is_corresponding":true,"raw_author_name":"Nathaniel Smith","raw_affiliation_strings":["Maple Health Group, LLC, New York, NY, USA"],"raw_orcid":"https://orcid.org/0000-0002-9215-8109","affiliations":[{"raw_affiliation_string":"Maple Health Group, LLC, New York, NY, USA","institution_ids":[]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5024836953","display_name":"Douglas T. Dieterich","orcid":"https://orcid.org/0000-0001-7786-8594","observed_orcids":["https://orcid.org/0000-0001-7786-8594"]},"institutions":[{"id":"https://openalex.org/I98704320","display_name":"Icahn School of Medicine at Mount Sinai","ror":"https://ror.org/04a9tmd77","country_code":"US","type":"education","lineage":["https://openalex.org/I1320796813","https://openalex.org/I98704320"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Douglas Dieterich","raw_affiliation_strings":["Icahn School of Medicine at the Mount Sinai School of Medicine, New York, NY, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Icahn School of Medicine at the Mount Sinai School of Medicine, New York, NY, USA","institution_ids":["https://openalex.org/I98704320"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":3,"corresponding_author_ids":["https://openalex.org/A5101772448"],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":0.7969,"has_fulltext":false,"cited_by_count":13,"citation_normalized_percentile":{"value":0.71848524,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":93,"max":98},"biblio":{"volume":"20","issue":"3","first_page":"251","last_page":"257"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10151","display_name":"Hepatitis C virus research","score":0.899399995803833,"subfield":{"id":"https://openalex.org/subfields/2721","display_name":"Hepatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10151","display_name":"Hepatitis C virus research","score":0.899399995803833,"subfield":{"id":"https://openalex.org/subfields/2721","display_name":"Hepatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10804","display_name":"Health Systems, Economic Evaluations, Quality of Life","score":0.09920000284910202,"subfield":{"id":"https://openalex.org/subfields/2002","display_name":"Economics and Econometrics"},"field":{"id":"https://openalex.org/fields/20","display_name":"Economics, Econometrics and Finance"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}},{"id":"https://openalex.org/T11792","display_name":"Pharmaceutical Economics and Policy","score":0.00019999999494757503,"subfield":{"id":"https://openalex.org/subfields/2002","display_name":"Economics and Econometrics"},"field":{"id":"https://openalex.org/fields/20","display_name":"Economics, Econometrics and Finance"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/chronic-hepatitis-c","display_name":"chronic hepatitis C","score":0.9950000047683716},{"id":"https://openalex.org/keywords/sofosbuvir-velpatasvir","display_name":"sofosbuvir/velpatasvir","score":0.9589999914169312},{"id":"https://openalex.org/keywords/glecaprevir-pibrentasvir","display_name":"glecaprevir/pibrentasvir","score":0.9380000233650208},{"id":"https://openalex.org/keywords/voxilaprevir","display_name":"voxilaprevir","score":0.9330000281333923},{"id":"https://openalex.org/keywords/ribavirin","display_name":"ribavirin","score":0.8149999976158142},{"id":"https://openalex.org/keywords/retreatment","display_name":"retreatment","score":0.7300000190734863},{"id":"https://openalex.org/keywords/cost-effectiveness","display_name":"cost-effectiveness","score":0.968999981880188},{"id":"https://openalex.org/keywords/quality-adjusted-life-years","display_name":"quality-adjusted life years","score":0.9139999747276306},{"id":"https://openalex.org/keywords/lifetime-costs","display_name":"lifetime costs","score":0.7440000176429749},{"id":"https://openalex.org/keywords/markov-state-transition-model","display_name":"Markov state-transition model","score":0.8009999990463257},{"id":"https://openalex.org/keywords/hepatitis-c-elimination","display_name":"HCV elimination","score":0.5210000276565552},{"id":"https://openalex.org/keywords/united-states","display_name":"United States","score":0.5479999780654907}],"concepts":[{"id":"https://openalex.org/C2778390639","wikidata":"https://www.wikidata.org/wiki/Q2502747","display_name":"Sofosbuvir","level":5,"score":0.8379337787628174},{"id":"https://openalex.org/C2780040827","wikidata":"https://www.wikidata.org/wiki/Q421862","display_name":"Ribavirin","level":4,"score":0.7049055695533752},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.6623397469520569},{"id":"https://openalex.org/C2776455275","wikidata":"https://www.wikidata.org/wiki/Q154869","display_name":"Hepatitis C","level":2,"score":0.47491559386253357},{"id":"https://openalex.org/C2776408679","wikidata":"https://www.wikidata.org/wiki/Q708693","display_name":"Hepatitis C virus","level":3,"score":0.47058573365211487},{"id":"https://openalex.org/C2908647359","wikidata":"https://www.wikidata.org/wiki/Q2625603","display_name":"Population","level":2,"score":0.44774019718170166},{"id":"https://openalex.org/C3020491458","wikidata":"https://www.wikidata.org/wiki/Q131742","display_name":"Chronic hepatitis","level":3,"score":0.4162179231643677},{"id":"https://openalex.org/C64332521","wikidata":"https://www.wikidata.org/wiki/Q614165","display_name":"Quality-adjusted life year","level":3,"score":0.4147476851940155},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.4023515284061432},{"id":"https://openalex.org/C3019080777","wikidata":"https://www.wikidata.org/wiki/Q1754768","display_name":"Cost effectiveness","level":2,"score":0.3778863251209259},{"id":"https://openalex.org/C159047783","wikidata":"https://www.wikidata.org/wiki/Q7215","display_name":"Virology","level":1,"score":0.18672585487365723},{"id":"https://openalex.org/C99454951","wikidata":"https://www.wikidata.org/wiki/Q932068","display_name":"Environmental health","level":1,"score":0.1560153067111969},{"id":"https://openalex.org/C2522874641","wikidata":"https://www.wikidata.org/wiki/Q808","display_name":"Virus","level":2,"score":0.14452621340751648},{"id":"https://openalex.org/C112930515","wikidata":"https://www.wikidata.org/wiki/Q4389547","display_name":"Risk analysis (engineering)","level":1,"score":0.0}],"mesh":[{"descriptor_ui":"D000998","descriptor_name":"Antiviral Agents","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D000998","descriptor_name":"Antiviral Agents","qualifier_ui":"Q000191","qualifier_name":"economics","is_major_topic":false},{"descriptor_ui":"D003362","descriptor_name":"Cost-Benefit Analysis","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004338","descriptor_name":"Drug Combinations","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005838","descriptor_name":"Genotype","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008390","descriptor_name":"Markov Chains","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D014481","descriptor_name":"United States","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016174","descriptor_name":"Hepacivirus","qualifier_ui":"Q000235","qualifier_name":"genetics","is_major_topic":true},{"descriptor_ui":"D016174","descriptor_name":"Hepacivirus","qualifier_ui":"Q000302","qualifier_name":"isolation & purification","is_major_topic":false},{"descriptor_ui":"D016896","descriptor_name":"Treatment Outcome","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D019057","descriptor_name":"Quality-Adjusted Life Years","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true},{"descriptor_ui":"D019698","descriptor_name":"Hepatitis C, Chronic","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D019698","descriptor_name":"Hepatitis C, Chronic","qualifier_ui":"Q000191","qualifier_name":"economics","is_major_topic":false},{"descriptor_ui":"D019698","descriptor_name":"Hepatitis C, Chronic","qualifier_ui":"Q000821","qualifier_name":"virology","is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1080/14737167.2019.1629291","doi":"https://doi.org/10.1080/14737167.2019.1629291","is_oa":false,"landing_page_url":"https://doi.org/10.1080/14737167.2019.1629291","pdf_url":null,"source":{"id":"https://openalex.org/S98544388","display_name":"Expert Review of Pharmacoeconomics & Outcomes Research","issn_l":"1473-7167","issn":["1473-7167","1744-8379"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["abdc-c","anvur-scientific","cwts-core","dongbi-d","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320547","host_organization_name":"Taylor & Francis","host_organization_lineage":["https://openalex.org/P4310320547","https://openalex.org/P4310320449"],"host_organization_lineage_names":["Taylor & Francis","Informa"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Expert Review of Pharmacoeconomics & Outcomes Research","raw_type":"journal-article"},{"id":"pmid:31204882","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/31204882","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Expert review of pharmacoeconomics & outcomes research","raw_type":"Comparative Study"}],"best_oa_location":null,"sustainable_development_goals":[{"score":0.98580002784729,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[{"id":"https://openalex.org/F4320308573","display_name":"Gilead Sciences","ror":"https://ror.org/056546b03"}],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":36,"referenced_works":["https://openalex.org/W1512398135","https://openalex.org/W1583807094","https://openalex.org/W1591703875","https://openalex.org/W1604557454","https://openalex.org/W1950975653","https://openalex.org/W1984413237","https://openalex.org/W1987856531","https://openalex.org/W1996796934","https://openalex.org/W2003307697","https://openalex.org/W2009801818","https://openalex.org/W2016071077","https://openalex.org/W2020450628","https://openalex.org/W2022786152","https://openalex.org/W2023149416","https://openalex.org/W2041643208","https://openalex.org/W2045245188","https://openalex.org/W2047033934","https://openalex.org/W2061799663","https://openalex.org/W2067182451","https://openalex.org/W2077550422","https://openalex.org/W2078799829","https://openalex.org/W2083200314","https://openalex.org/W2117766751","https://openalex.org/W2127497497","https://openalex.org/W2143456878","https://openalex.org/W2162317388","https://openalex.org/W2178511310","https://openalex.org/W2189030627","https://openalex.org/W2311331156","https://openalex.org/W2520731166","https://openalex.org/W2521182006","https://openalex.org/W2750519500","https://openalex.org/W2793184159","https://openalex.org/W2900195724","https://openalex.org/W2979856778","https://openalex.org/W4254843569"],"related_works":["https://openalex.org/W2955877669","https://openalex.org/W2970207351","https://openalex.org/W2806304753","https://openalex.org/W4281713723","https://openalex.org/W2529545144","https://openalex.org/W4200566836","https://openalex.org/W2101533631","https://openalex.org/W3100924188","https://openalex.org/W3108414539","https://openalex.org/W2097068106"],"abstract_inverted_index":{"OBJECTIVES:":[0],"Given":[1],"the":[2,38,69,125,176,182,191],"goal":[3],"of":[4,17,40,54,91,155],"hepatitis":[5,19],"C":[6,20],"virus":[7],"elimination":[8],"by":[9,85,117,168],"2030,":[10],"World":[11],"Health":[12],"Organization":[13],"guidelines":[14],"recommend":[15],"treatment":[16,127,146,184,193],"chronic":[18],"(CHC)":[21],"with":[22],"pan-genotypic":[23,41],"direct-acting":[24],"antivirals,":[25],"such":[26],"as":[27],"sofosbuvir/velpatasvir":[28],"(SOF/VEL),":[29],"SOF/VEL/voxilaprevir":[30],"(VOX)":[31],"or":[32,46,51,80],"glecaprevir/pibrentasvir":[33],"(GLE/PIB).":[34],"The":[35],"study":[36],"evaluated":[37],"cost-effectiveness":[39],"regimens":[42,134],"in":[43,120,152,162,175],"initial":[44],"(SOF/VEL":[45],"GLE/PIB)":[47],"and":[48,65,83,97,102],"re-treatment":[49],"(SOF/VEL/VOX":[50],"GLE/PIB+SOF+ribavirin":[52],"(RBV))":[53],"CHC.":[55],"METHODS:":[56],"A":[57],"Markov":[58],"state-transition":[59],"model":[60,112],"projected":[61],"lifetime":[62,104,141,198],"CHC":[63,178],"health":[64],"economic":[66],"outcomes":[67,88],"from":[68,77],"US":[70],"payer":[71],"perspective.":[72],"Model":[73,87],"inputs":[74],"were":[75,109,160],"sourced":[76],"clinical":[78],"trials":[79],"published":[81],"literature":[82],"validated":[84],"hepatologists.":[86],"included":[89],"numbers":[90],"advanced":[92],"liver":[93],"disease":[94],"events,":[95],"life-years":[96,99],"quality-adjusted":[98],"(QALYs)":[100],"gained,":[101],"total":[103],"costs.":[105,199],"One-way":[106],"sensitivity":[107,163],"analyses":[108],"performed":[110],"on":[111,187],"results.":[113],"RESULTS:":[114],"SOF/VEL":[115,166,192],"followed":[116,167],"SOF/VEL/VOX":[118,169],"resulted":[119],"comparable":[121,172],"cure":[122,173],"rates":[123,174],"to":[124,171,181,196],"GLE/PIB":[126,145,183],"pathway":[128,147,194],"(99.94%":[129],"vs.":[130,149],"99.93%,":[131],"respectively).":[132],"SOF-based":[133],"provided":[135],"similar":[136],"QALYs":[137],"at":[138],"a":[139,144],"lower":[140,197],"cost":[142,153],"versus":[143],"($30,749":[148],"$36,255),":[150],"resulting":[151],"savings":[154],"$5,506":[156],"per":[157],"patient.":[158],"Results":[159],"robust":[161],"analyses.":[164],"CONCLUSION:":[165],"leads":[170],"overall":[177],"population":[179],"relative":[180],"pathway.":[185],"Based":[186],"wholesale":[188],"acquisition":[189],"prices,":[190],"led":[195]},"counts_by_year":[{"year":2026,"cited_by_count":1},{"year":2025,"cited_by_count":4},{"year":2024,"cited_by_count":3},{"year":2022,"cited_by_count":3},{"year":2021,"cited_by_count":2}],"updated_date":"2026-10-31T12:09:11.096373","created_date":"2019-06-27T00:00:00"}